



Melanoma Surveillance Medicare Advantage Quick Reference Guide (QRG)

Cigna has partnered with eviCore® to provide Radiation Therapy Services for your Medicare Advantage patients. eviCore's clinical guidelines have been carefully researched and are continually updated in order to be consistent with the most current evidence-based guidelines and recommendations for the provision of radiation therapy. To avoid potential authorization denials, please follow this QRG for melanoma surveillance.

Surveillance/Follow-Up Melanoma Stage 0, IA, IB and IIA

- No routine advanced imaging indicated

Stage IIB, IIIA, and IIIB

Every 6 months for 5 years

- CT Chest (CPT® 71260) and Abdomen/Pelvis (CPT 74177) with contrast

Stage IIIC and IV Melanomas

Every 3 months for 3 years, then every 6 months for 2 years

- CT Chest (CPT® 71260) and Abdomen/Pelvis (CPT 74177) with contrast

Annually for 5 years for Stage IIIC and IV Melanomas

- MRI Brain without and with contrast (CPT 70553)

Questions? Please contact at clientservices@evicore.com

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Cigna HealthCare of South Carolina, Inc., Cigna HealthCare of North Carolina, Inc., Cigna HealthCare of Georgia, Inc., Cigna HealthCare of Arizona, Inc., Cigna HealthCare of St. Louis, Inc., HealthSpring Life & Health Insurance Company, Inc., HealthSpring of Florida, Inc., Bravo Health Mid-Atlantic, Inc., and Bravo Health Pennsylvania, Inc. The Cigna name, logos, and other Cigna marks are owned by Cigna Intellectual Property, Inc.

INT_19_79452_C